Dow Jones 10412.82 -50.23 6:25 pm PST, August 30, 2005  NASDAQ 2129.76 -7.89 For info, visit access.smallcapnetwork.com S & P 500 1208.41 -3.87 Change your subscription status here Russell 2000 653.76 -1.56 VOLUME 05: ISSUE 66  Feature: MIV Therapeutics - Impressive Rise. More Patents Filed. In March 2005, we were already convinced of the potential for biotech and medical device company MIV Therapeutics (OTCBB: MIVT) when we Alerted the readership to the shares at 34 cents. However, even to our typically cynical eyes, the recent rapid price progress and attendant great trade action has been nothing short of outstanding.  For risk-oriented investors, this pullback in MIVT --and any further dips--could well be used to accumulate shares or replace some sold on the last run. Stops should be used on new purchases or to protect profits, but watch for the whipsaw. Check the SmallCap newsletter archives (and the SCBLOG) for our extensive past coverage of this unique, cutting edge biotech: http://access.smallcapnetwork.com/archives.php?company=MIVT&year=2005. Speaking of the SCBLOG, investors that regularly access that site were privy to our thoughts as the shares powered through $1 last week and hit a new all time high of $1.75, yesterday. We suggested partial sales at levels over $1 to both lower an initial cost base and reduce risk. Volatility apparently won out as the shares pulled back from a close of $1.55 Monday, to a low of $1.13, Tuesday. We can unearth no material reason for the decline other than some profit taking, which is reasonable given the activity. We believe, however, that the selling has likely been overdone. The shares closed at $1.27, Tuesday.  At that closing price, shares purchased at or near our trading alert price of 34 cents in March have already seen an almost 300 percent rise. This weekly chart evidences that volumes have been impressive--over 1 million shares a day traded for the last week. Three million shares changed hands Monday alone with a like amount Tuesday. That's impressive. The shares completed a swift .382 retracement, Tuesday of the run established over the last few months. It's apparent that a growing group of traders and investors have found this stock. There is apparently significant interest out of Europe as the shares are also listed in Frankfurt. MIVT announced after the close, Tuesday, (release below) that it and a technology development partner, The University of British Columbia, have applied for two more patents, which further build on the company's previous work to vastly improve the therapeutic functionality of implantable medical devices such as cardiac stents. We believe that there will be more to come as the company builds its intellectual property portfolio. As investors know, in the biotech arena, patents are the currency of success. We've seen that with others in our stable including reader favorite Biophan (OTCBB: BIPH). Intellectual property is the vehicle that opens doors and secures partnerships with large companies that see the value in licensing over development, such as the Biophan and Boston Scientific (NYSE: BSX) deal mentioned here previously. From today's release MIV Therapeutics CEO Alan Lindsay states:   "By continuing to expand this valuable intellectual property portfolio, we are not only effectively safeguarding our Company's commercial viability and competitive edge, but also potentially contributing to the advancement and enhancement of critical medical care." In a nutshell, here's the bottom-line for MIV Therapeutics from another recent press release:  "Its (MIVT's) technology could offer the worldwide healthcare industry an attractive, safer and more viable alternative to polymer coatings currently on the market." Couldn't have said it better myself.  MIV has produced an informative slide show giving an overview of its proprietary Hydroxyapatite coating technology as it applies to prolonging the life, improving the safety and enhancing the efficacy of implantable devices. Access it here--http://www.trilogy-capital.com/tcp/index.htm by entering your email address.     PRESS RELEASE MIV Therapeutics Further Expands IP Portfolio with Milestone Addition of Two New U.S. Provisional Patent Applications Leading Biomedical Innovator Provides New Coating Technologies for Next Generation of Drug-Eluting Implantable Medical Devices VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 30, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug delivery technologies for the treatment of cardiovascular disease, announced today a major milestone in further expanding its intellectual property rights with the filing of two new U.S. patent applications by the University of British Columbia, a technology development partner of MIVT. The two patent applications pertain to technologies for effectively applying novel coatings onto metal medical devices to achieve desired therapeutic benefits. Both of these technologies carry considerable potential to improve the therapeutic functionality of implantable medical devices, such as metal stents. "These latest technological leaps provide additional validation of our innovation and potential to significantly impact the biomedical marketplace," said CEO Alan Lindsay. "By continuing to expand this valuable intellectual property portfolio, we are not only effectively safeguarding our Company's commercial viability and competitive edge, but also potentially contributing to the advancement and enhancement of critical medical care. These latest patent applications are a source of great pride and gratification to our team and to the ceramic scientists at the University of British Columbia." Significantly, these technologies build on earlier coating technologies developed by MIVT, which could have a substantial impact on the methods in which metal medical devices will be coated in the future to achieve optimal biocompatibility, safety and efficacy. Unlike the medical coatings commonly in use today, MIVT's proprietary "HAp" coatings are based on a substance that is already naturally found in the human body known as hydroxyapatite. MIVT's innovative coating technologies are designed to inhibit adverse reactions of the immune system. MIV Therapeutics is committed to providing improved solutions for the treatment of cardiovascular disease and other conditions. In collaboration with the University of British Columbia, MIVT is focused on developing proprietary HAp coating formulations to protect surrounding tissue from chemical interaction with bare-metal stents, an interaction which typically causes an aggressive immune response, resulting in restenosis, or re-narrowing of arteries, and a risk of thrombus in the stented artery. MIVT's novel coatings are based upon a natural material, Hydroxyapatite, a component of hard tissue found in human teeth and bone, which enables the surface of metallic stents to virtually mimic the natural state of structurally-sound 100% biocompatible and bio-active tissue. The Company believes its technology also has potential for an array of additional medical applications, including dental, hip and bone repair implants. About MIV Therapeutics, Inc. MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and superior healing properties pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit: http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.  Contact: MIV Therapeutics Inc. Investor Relations, 604-301-9545 Toll-free: 800-221-5108 Fax: 604-301-9546 E-mail: investor@mivtherapeutics.com Web: www.mivtherapeutics.com Or for Product Inquiries and Business Opportunities: Arc Rajtar, 604-301-9545 Ext. 22 arajtar@mivi.ca or Trilogy Capital Partners Paul Karon, Toll-free: 800-342-1467 paul@trilogy-capital.com     Source: MIV Therapeutics, Inc.      We Value Your Feedback Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 3525 Del Mar Heights Rd #334 San Diego, CA 92130 Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The SmallCap Digest is an independent electronic publication committed to providing our readers with factual information on selected  publicly traded companies. SmallCap Digest is not a licensed investment professional or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward  maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features for the publication and circulation of the SmallCap Digest or representation on SmallCapNetwork.net.  Likewise, this newsletter is owned by TGR Group, LLC.  To the degrees enumerated herein,  this newsletter should not be regarded as an independent publication. Visit Here to view our compensation on every company we have ever covered, or visit the following web address:  http://access.smallcapnetwork.com/compensation_disclosure.html for our full compensation disclosure and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts compensation and disclosure. TGR Group LLC has also been paid a fee of $30,000 by MIV  Therapeutics  for coverage of the company. In addition, TGR Group LLC has been awarded 272,000 warrants with an exercise price of $.26 by Trilogy Capital Partners for coverage of MIV  Therapeutics. Additionally, Some of the companies featured in the SmallCap Digest Newsletter pay an ESP (Electronic Service Provider) fee to an affiliated Technology Company for electronic delivery of this newsletter and other web related technology services. Fees range from $3,000 to $5,000 per month. All statements and expressions are the sole  opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the newsletter is neither an offer nor solicitation to buy or sell any securities  mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. From time to time TGR Group LLC sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies. The editor, members of the editor's family, and/or entities with  which the editor is affiliated aside from TGR Group LLC itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter. The profiles, critiques, and other editorial content of the SmallCap Digest and SmallCapNetwork.net may contain statements that appear forward as it relates to the expected capabilities of the companies mentioned herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN  SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN  CONSENT OF THE EDITORS OF SMALLCAPNETWORK.NET. We encourage our readers to invest carefully and read the investor information available at the web sites of  the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at  http://www.sec.gov/consumer/cyberfr.htm . Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.